CARTANA’s In Situ Sequencing solution enables simultaneous analysis of hundreds of genes within all cells comprising a tissue, without losing tissue morphology, with high sensitivity and throughput in several research areas. The costs avoided on reagents and technical hours when analyzing “-omics” at scale will make 10X able to out price many of their competitors that don’t use in situ analysis.

In Situ analysis will be able to save 10X an estimated $15 per sample by avoiding the process of isolating nucleic acids from the cells. In addition to supporting discoveries made by the Chromium and Visium platforms, In Situ will broaden the range of customers and enable new translational and clinical applications. With In Situ, 10x Genomics expects to establish the foundation for a third technology platform. These platforms can analyze large amounts of single cells and mRNA transcriptomes, respectively. These approaches work well with the company’s existing Chromium Single Cell and Visium Spatial platforms. In Situ approaches will give scientists the ability to directly measure large numbers of molecules in tissue by capturing the precise location of those molecules at sub-cellular resolution. The resources from ReadCoor and CARTANA will give 10x Genomics comprehensive and foundational intellectual property, key technology advances, and deep talent and expertise in this emerging field. Wanting to take advantage of available talent, 10X Genomics has added founders, George Church of ReadCoor and Mats Nilsson (a pioneer in In Situ sequencing) of CARTANA to its scientific advisory board. ReadCoor and CARTANA came out of laboratories at Harvard and Stockholm University, respectively and both founders are experts in their fields’. The company will provide further details on the market opportunity and product strategy at a future date. 10x can pay for both transactions with a combination of cash from its balance sheet as well as shares of stock. Stockholm-based CARTANA AB specializes in mapping gene expression in brain tissue using their In Situ RNA analysis technology.Īs a result of these purchases, 10x Genomics will acquire over 110 patents and applications that cover multiple foundational In Situ (on-site) analysis approaches and swell its already beefy patent portfolio of over 825 issued patents and applications. The announcement follows its late August acquisition of CARTANA AB for a sum of $41.2 million. 1 0x Genomics, Inc, trading on the Nasdaq as TXG, announced on October 5th that it has agreed to acquire ReadCoor, Inc., developer of foundational In Situ technologies, based in Boston, for cash and stock consideration of $350 million.

10x chromium boston